Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
September 06, 2024
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical CareSeptember 06, 2024 Eversheds Sutherland has advised Edwards Lifesciences on the US$4.2bn sale of its Critical Care product group to Becton, Dickinson and Company (BD). Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease. The Critical Care product group is an industry leader in advanced patient monitoring with advanced AI algorithms serving millions of patients globally. Key contacts
Lee Harris Partner United Kingdom Antony Walsh Partner United Kingdom Barri Mendelsohn Partner United Kingdom Rachel Cooper Partner United Kingdom Edward M. Tompkin-Haag Partner United Kingdom Kelly Holmes Partner United Kingdom Philip Crosbie Partner United Kingdom Christopher Murray Partner United Kingdom Latest News
Latest Events
firm news July 01, 2026 Eversheds Sutherland lands lateral partner-led Paris Funds team, as its wid... firm news July 01, 2026 Strengthening our life sciences and regulatory capability with key hire in ... client news June 17, 2026 Advising Trane Technologies on the acquisition of Transport-Kälte-Vertrieb ... firm news June 15, 2026 virtual Energy Transition Series - Project Financing BESS: Comparing the UK market ... July 08, 2026 10:00 ET | 15:00 BST | 16:00 CET virtual UAE - Employment law in the Dubai International Financial Centre September 10, 2026 9.30am - 1.30pm (GMT) Virtual in-person September 10, 2026 9.30am - 1.00pm (BST) London, United Kingdom in-person September 17, 2026 9.30am - 4.30pm (GMT) London, United Kingdom |